Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 288-291, 2003.
Article
in English
| WPRIM
| ID: wpr-356815
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the therapeutic efficacy of compound immunotherapy of tumor-derived heat shock protein 70 (HSP70) and interleukin-2 (IL-2) on tumor-bearing mice, and to provide reference for translating this strategy to human cancer.</p><p><b>METHODS</b>Cell culture, techniques for protein extraction and purification, SDS-PAGE, Western blot and capillary electrophoresis for HSP70 detection and purity analysis, and animal experiments were used. Mice were treated with HSP70 5 or 10 microg and IL-2 50 kU, 100 kU or 2 kU (maintaining dosage) at previously designated intervals.</p><p><b>RESULTS</b>Both the mono-administration of either HSP70 or IL-2 and the compound immunotherapy of HSP70 and IL-2 obviously inhibited the growth of the implanted tumor and prolonged the life span of the mice to different extents. However, long periods of tumor-free survival (over 90 days) were demonstrated only in HSP70 10 micro g group, HSP70 10 microg-IL-2 50 kU group, and HSP70 10 microg-IL-2 100 kU group (40%, 40%, 60% respectively). On the other hand, none of the mice in the rest groups achieved long-term survival. Statistical significance was apparent in comparison with the groups without long period survival (P < 0.025 - 0.05).</p><p><b>CONCLUSION</b>Our research revealed that tumor-derived HSP70 immunotherapy was much more effective than IL-2 alone. And in compound immunotherapy, HSP70 was the main factor in delaying or eradicating the tumors. The proper combination of HSP70 and IL-2 (10 microg HSP70 and 100 kU IL-2 in this experimental mouse model) clearly enhanced the immunotherapy efficacy which indicated that the specific immunotherapy as a main part of tumor immunotherapy assisted by cytokine immunotherapy would be a promising strategy in cancer treatment.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Tumor Cells, Cultured
/
T-Lymphocytes, Cytotoxic
/
Survival Rate
/
Mortality
/
Interleukin-2
/
HSP70 Heat-Shock Proteins
/
Therapeutic Uses
/
Drug Therapy, Combination
/
Allergy and Immunology
Type of study:
Prognostic study
Limits:
Animals
Language:
English
Journal:
Chinese Medical Journal
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS